-
Looking at CAD through the PERISCOPE; Addressing Agitation and Aggression in Persons with Advanced Dementia; It Used To Be Easier To Treat Sinusitis; CAC: A kinder, Gentler Way to Predict Cardiovascular Risk; Was Mae West Right? CV Risk Reduction: Too Much of A Good Thing is Wonderful; Midlife Contraception
-
-
-
CHICAGO Growth in the cardiovascular device market has slowed recently as safety issues with first-generation drug-eluting stents (DES) have combined with controversy re-garding the benefits of interventional therapy, compared to medical treatment, to drive decreased utilization.
-
A combination of disappointing data and urging by a panel of physicians against blockbuster cholesterol drug Vytorin dented two pharma giants, as the annual meeting of the American College of Cardiology (Washington) got under way in Chicago.
-
Clot-busting drug therapy, when administered to patients after a stroke, appears to work more effectively if the patient already has been on an anti-platelet medication. However, this might also increase the risk for bleeding within the brain.
-
One of the ongoing battles pitting "minimally invasive" against open surgical approaches is in clearing the carotid arteries to avoid stroke, or as therapy following stroke.
-
The Centers for Medicare & Medicaid have been especially busy in the cardiovascular sector the past few weeks, resisting coverage, or added coverage, in some areas, approving broader coverage in at least one sector.
-
CardioMind (Sunnyvale, California), an under-the-radar developer of coronary stents, has its eye on a specific, underserved sector of the drug-eluting stent (DES) sector: the worldwide market for vessel "scaffold" devices.
-
A study assessing Boston Scientific's (Natick, Massachusetts) EZ FilterWire to catch bits of plaque and blood clot that break loose during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome has been discontinued after it failed to show that it can reduce rates of major cardiovascular complications.
